Share Rare Daily Staff Global Blood Therapeutics entered into an agreement with Sanofi to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease: one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress. These mechanisms are distinct and potentially complementary to that of GBT’s Oxbryta, a novel hemoglobin S polymerization small molecule inhibitor approved in the United States for the treatment of Sickle Cell Disease in patients ages 12 years and older. The programs, from Sanofi’s Bioverativ subsidiary, supplement GBT’s existing pipeline and support the company’s strategy to address SCD from multiple approaches.